- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01602510
Lamotrigine Phase III Study in Bipolar I Disorder
A Fixed-Dose Study of Lamotrigine Versus Placebo in the Long Term Prevention of Relapse and/or Recurrence of a Manic, Hypomanic, Mixed or Depressive Episode in Adult Subjects With Bipolar I Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100083
- GSK Investigational Site
-
Beijing, China, 100088
- GSK Investigational Site
-
Beijing, China, 100096
- GSK Investigational Site
-
Shanghai, China, 200030
- GSK Investigational Site
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510180
- GSK Investigational Site
-
Guangzhou, Guangdong, China, 510370
- GSK Investigational Site
-
Guangzhou, Guangdong, China, 510630
- GSK Investigational Site
-
-
Hebei
-
Baoding, Hebei, China, 071000
- GSK Investigational Site
-
Shijiazhuang, Hebei, China, 050000
- GSK Investigational Site
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150070
- GSK Investigational Site
-
-
Henan
-
Changsha, Henan, China, 410011
- GSK Investigational Site
-
Xinxiang, Henan, China
- GSK Investigational Site
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- GSK Investigational Site
-
-
Hunan
-
Changsha, Hunan, China
- GSK Investigational Site
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- GSK Investigational Site
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710032
- GSK Investigational Site
-
-
Shanxi
-
Taiyuan, Shanxi, China
- GSK Investigational Site
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- GSK Investigational Site
-
-
Yunnan
-
Kunming, Yunnan, China, 650032
- GSK Investigational Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- GSK Investigational Site
-
Hangzhou, Zhejiang, China, 310003
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For open label phase
- Subjects must be able to effectively communicate with study personnel, have the ability to comprehend the key components of the Inform Consent Form and must provide written informed consent to participate in the study prior to any study-specific assessments or procedures.
- An in-patient or out-patient (male or female) and aged >=18 years old.
Disease to be studied: Has a diagnosis of the following disease as defined by DSM-IV criteria currently or within 60 days:
a)Bipolar I Disorder, most recent episode depressed (296.5x); b)Bipolar I Disorder, most recent episode hypomanic (296.40); c)Bipolar I Disorder, most recent episode manic (296.4x); d)Bipolar I Disorder, most recent episode mixed (296.6x)
- The subject who has a diagnose of "bipolar I disorder, most recent episode depressed (296.5x)" must meet the following criteria:
Has at least one well documented manic, hypomanic or mixed episode, as defined by DSM-IV criteria, within 3 years of enrolment ; The duration of recent/current depressive episode is at least 2 weeks but not longer than 12 months prior to enrolment; For subject with currently experiencing a depressive episode, he/she must have a minimum total score of 18 on the HAMD-17 at s screening.
- The subject who has a diagnosis of "bipolar I disorder, most recent episode hypomanic (296.40)" or "bipolar I disorder, most recent episode manic (296.4x)" or "bipolar I disorder, most recent episode mixed (296.6x)" must meet the following criteria: Has had at least one well documented additional manic, hypomanic or mixed episode and one depressed episode, as defined by DSM-IV criteria, within 3 years of enrolment; Has a duration of the index manic episode of at least 1 week (unless hospitalised) or hypomanic episode of at least 4 days or mixed episode of at least 1 week. In neither case should the index episode be more than 12 months in duration; If the subject's index episode is the subject's initial/current manic mood event, subject must have a minimum score of 10 on the first 11 items of the YMRS at screening; If the subject's index episode is the subject's initial/current mixed mood event, subject must have a minimum score of 10 on the first 11 items of the YMRS, and have a minimum score of 18 on the HAMD-17 at screening.
For randomized double-blind phase
- Has been on Lamotrigine 200 mg/day monotherapy for at least 1 week.
- CGI-S score <= 3 for at least 4 continuous weeks of treatment prior to randomization.
- Has demonstrated adequate compliance with IP (compliance rate: 75%-125%, inclusive).
Exclusion Criteria:
For open label
- Has met Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria for rapid cycling and has had more than 4 manic, hypomanic, mixed or depressive episodes in the 12-month period prior to enrollment.
- Has a significant DSM-IV Axis II diagnosis which would suggest non-responsiveness to pharmacotherapy for bipolar disorder or non-compliance with the protocol.
- Has a current or previous diagnosis of an Axis I disorder (including anorexia nervosa or bulimia nervosa) with the exception of bipolar disorder or has received corresponding treatment, or has been diagnosed with dysthymia within the previous 2 years.
- Has signs or symptoms of psychosis.
- The subject, in the investigator's judgment, poses a suicidal risk, has attempted suicide within 6 months prior to screening (assessed using the Columbia Suicide Severity Rating Scale Baseline) or .
- Has documented Intelligence quotient < 70 or suspected mental retardation.
- Has a history of substance abuse or dependence within 12 months prior to enrolment (DSM-IV defined substance categories, excluding nicotine and caffeine and including alcohol), or has as a positive urine test for illicit drug use (excluding nicotine and caffeine).
- Has received fluoxetine within 4 weeks prior to entry into the open-label phase; has received oral contraceptives or other hormonal preparations containing estrogen within 2 weeks prior to entry into the open-label phase; has received lopinavir/ritonavir or atazanavir /ritonavir within 7 days prior to the baseline visit.
- Has a clinically significant and/or unstable medical disorder (with or without lab test results); or clinically significant test results (thyroid function, electrocardiogram, hematology, clinical chemistry, or urinalysis) as per investigator's judgment; or a disorder that would interfere with the action, absorption, distribution, metabolism, or excretion of lamotrigine; per investigator's clinical judgment (after consulting GSK medical monitor), might pose a safety concern; or interfere with the accurate assessment of safety or efficacy.
- Has a history or current diagnosis of epilepsy.
- Is morbidly obese, i.e. if Body Mass Index (BMI) is > 35 {BMI = Body weight (in kg) divided by (Height in meters squared).
- Single or average QT interval corrected by Bazette's formulaQTcB or QTc > 450 millisecond (msec); for patients with bundle branch block QTc > 480 msec.
- Has a history of hepatic dysfunction; Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) >= 2 x upper limit of normal (ULN); Alkaline phosphatase (ALP) or total bilirubin > 1.5 x ULN (excluding total bilirubin > 1.5 x ULN but direct bilirubin < 35%) or other conditions which, in the investigator's judgment, would render patients unsuitable for the study.
- Has a history of drug allergy (including rash) or a medically significant adverse effect from any ingredient of lamotrigine, or a history of rash due to anti-epileptic drugs or has frequent and/or serious hypersensitivity reaction to multiple drugs.
- Participation in any study related to lamotrigine within 6 months before screening or has received lamotrigine within 4 weeks before screening.
- Participation in another clinical study unrelated to the current illness currently or within the previous 30 days, or 3 months for studies related to the current illness.
- Initiation of systematic psychotherapy within 3 months prior to screening or planned initiation of systematic psychotherapy during the study.
- Female subjects who are pregnant, lactating or do not agree to use the contraceptive methods such as use of condom, injection of progesterone, a reliable barrier method of birth control, partner with vasectomy or abstinence during the study.
For randomized double blind phase
- Has signs or symptoms of psychosis.
- Requires treatment for a manic or mixed episode in the open-label phase with new courses of lithium, psychotropic drugs or other drugs with a half-life greater than 14 days.
- Has become actively suicidal and/or has a score >=3 on item 3 of the HAMD.
- Has tested positive for an illicit drug on lab analysis administered before randomization or alcohol abuse/addiction.
- Has had a change in lamotrigine dosage during the last week of the open-label phase.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo
|
Experimental: Lamotrigine CD
lamotrigine chewable dispersible tablets 25mg, 50mg, 100mg
|
in the double blind phase, lamotrigine 200mg/day will be used among half of eligible subjects after randomization
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Intervention for Any Mood Episode (TIME)
Time Frame: 36 weeks (wks)
|
TIME is defined as being the time from entry into the randomized double-blind phase to the time of the first prescription of any additional pharmacotherapy or Electroconvulsive therapy (ECT) determined by the investigator to be necessary for treatment of a relapse and/or recurrence of a depressive, manic, hypomanic or mixed episode, whichever occurs first.
TIME was measured relative to randomization date.
Par.
prematurely discontinued from the study prior to reaching the TIME event were censored at the time of discontinuation.
Analysis was performed using Cox proportional hazards regression model with covariates of site, CGI-S baseline score, treatment and treatment by CGI-S baseline score interaction.
The overall hazard ratio for treatment group could not be calculated due to different CGI-S baseline score level.
|
36 weeks (wks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Intervention for Manic, Hypomanic or Mixed Episode (TIMan)
Time Frame: 36 weeks
|
TIMan was analyzed using using Cox proportional hazards regression model with covariates of site, CGI-S baseline score, treatment and treatment by CGI-S baseline score interaction.
The overall hazard ratio for treatment group could not be calculated due to different CGI-S baseline score level.
Par.
prematurely discontinued from the study prior to reaching the event were censored at the time of discontinuation.
|
36 weeks
|
Time to Intervention for Depressive Episode (TIDep)
Time Frame: 36 weeks
|
TIDep was analyzed using Cox proportional hazards regression model with covariates of site, CGI-S baseline score, treatment and treatment by CGI-S baseline score interaction.
The overall hazard ratio for treatment group could not be calculated due to different CGI-S baseline score level.
Par.
prematurely discontinued from the study prior to reaching the event were censored at the time of discontinuation.
|
36 weeks
|
Overall Survival in Study (TIME-SIS).
Time Frame: 36 weeks
|
TIME-SIS was defined as the time to intervention (addition of pharmacotherapy or ECT) for any mood episode, or to the time when the participant is withdrawn for any reason after randomization.
The premature discontinuation of a participant prior to reaching TIME, for any reason, was treated as an event related to bipolar disorder.
All participants prematurely discontinued prior to the TIME event in this analysis were to be assumed to have reached TIME.
TIMS-SIS was analyzed using Cox proportional hazards regression model with covariates of site, CGI-S baseline score, treatment and treatment by CGI-S baseline score interaction.
The overall hazard ratio for treatment group could not be calculated due to different CGI-S baseline score level.
Par.
prematurely discontinued from the study prior to reaching the event were censored at the time of discontinuation.
|
36 weeks
|
Change From Baseline in Clinical Global Impression of Improvements (CGI-I)
Time Frame: Baseline and up to 36 weeks
|
The CGI-I is a 7-point scale where investigator were asked to assess the participant's illness at the time of assessment (improved or worsened) relative to a baseline state.
In this scale, 1= very much improved; 2= much improved; 3= minimally improved; 4= no change; 5= minimally worse; 6= much worse; or 7= very much worse.
Analysis was performed using Analysis of covariance with covariates of site, CGI-S baseline score and treatment.
In presented Last-observation-carried-forward datasets, the last non-missing on therapy (OT) score prior to TIME was carried forward to estimate missing data points for the remaining study visits of the treatment period.
Baseline value was defined as the last non-missing values at or prior to the randomization.
Change from baseline at the time point of interest was calculated by subtracting the baseline values from the individual post-baseline values.
If either baseline or post-baseline value was missing, the change from baseline was set to missing.
|
Baseline and up to 36 weeks
|
Change From Baseline in Clinical Global Impression of Severity (CGI-S)
Time Frame: Baseline and up to 36 weeks
|
The CGI-S is a 7-point scale where investigator were asked to rate the severity of the participant's illness at the time of assessment on severity of mental illness, where 1= normal, and 7= extremely ill.
Data was collected on Weeks 0, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 32 and 36.
Analysis performed using Analysis of Covariance (ANCOVA) with covariates of site, CGI-S baseline score (Open label phase), treatment and CGI-S baseline score.
In presented Last observation carried forward (LOCF) datasets, last non-missing on therapy score prior to TIME was carried forward to estimate missing data points for remaining study visits of treatment period.
The baseline value was defined as last non-missing values at or prior to the randomization.
The change from baseline at the time point of interest was calculated by subtracting the baseline values from individual post-baseline values.
If either the baseline or post-baseline value was missing, the change from baseline was set to missing as well.
|
Baseline and up to 36 weeks
|
Change From Baseline in Hamilton Depression Rating Scale (HAMD)
Time Frame: Baseline and up to 36 weeks
|
HAMD consists of 17 items: depressed mood, feelings of guilt, suicide, insomnia-early, middle, late, work and activities, retardation, agitation, anxiety psychic, anxiety somatic, somatic symptoms gastro-intestinal, general somatic symptoms, hypochondriasis, loss of weight, and insight.
Investigators rated par.
from 0 to 4 (or 2) for these items.
Total score is sum of all subscales (0 to 52, higher is worse).
Data was collected on Wks 0, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 36.
Analysis was performed using ANCOVA with covariates of site, CGI-S baseline (BL) score, treatment and HAMD total BL score.
The last non-missing OT score prior to TIME was carried forward to estimate missing data points for remaining study visits of the treatment period.
BL value was defined as the last non-missing value at or prior to the randomization.
Change from BL was calculated by subtracting BL from the specific post-BL value.
If BL or post-BL value was missing, the change from BL was set to missing.
|
Baseline and up to 36 weeks
|
Change From Baseline in Young Mania Rating Scale (YMRS) Total Score
Time Frame: Baseline and up to 36 weeks
|
YMRS consists of 11 items: Elevated Mood, Increased Motor Activity/Energy, Sexual Interest, Sleep, Irritability, Speech, Language/Thought Disorder, Content, Disruptive/Aggressive Behaviour, Appearance, and Insight.
Investigators rated par.
from 0 to 4 (or 8) for each of these items.
Total score is the sum of all subscales, from 0 to 60 (higher is worse).
Data was collected on Wks 0, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 36.
Analysis was performed using ANCOVA with covariates of site, CGI-S BL score, treatment and YMRS total BL score.
In LOCF datasets, the last non-missing OT score prior to TIME was carried forward to estimate missing data points for the remaining study visits of the treatment period.
BL value was defined as the last non-missing values at or prior to the randomization.
Change from BL at the time point of interest was calculated by subtracting BL value from the individual post-BL value.
If either the BL or post-BL value was missing, change from BL was set to missing.
|
Baseline and up to 36 weeks
|
Change From Baseline of Global Assessment Scale (GAS) Total Score
Time Frame: Baseline and up to 36 weeks
|
For GAS, investigators rated par.
for lowest level of functioning during the previous week.
The scale has a 10 score categories: 1-10, 11-20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90, 91-100, using intermediary levels when appropriate (from 100 to 1, Lower is worse.).
Data was collected on Weeks 0, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 36.
Analysis was performed using ANCOVA with covariates of site, CGI-S BL score, treatment and GAS total BL score.
In presented LOCF datasets, the last non-missing on therapy score prior to TIME was carried forward to estimate missing data points for the remaining study visits of the treatment period.
The BL value was defined as the last non-missing values at or prior to the randomization.
The change from BL at the time point of interest was calculated by subtracting the BL values from the individual post-BL values.
If either the BL or post-BL value was missing, the change from BL was set to missing as well.
|
Baseline and up to 36 weeks
|
Change From Baseline in Body Weight
Time Frame: Baseline and up to 36 weeks.
|
Participant's body weight was measured on Weeks 0, 4, 8, 12, 16, 20, 24, 32 and 36.
Analysis was performed using ANCOVA with covariates of site, CGI-S baseline score, treatment and baseline body weight.
In presented LOCF datasets, the last non-missing on therapy score prior to TIME was carried forward to estimate missing data points for the remaining study visits of the treatment period.
The baseline value was defined as the last non-missing values at or prior to the randomization.
The change from baseline at the time point of interest was calculated by subtracting the baseline values from the individual post-baseline values.
If either the baseline or post-baseline value was missing, the change from baseline was set to missing as well.
|
Baseline and up to 36 weeks.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Bipolar and Related Disorders
- Bipolar Disorder
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Anticonvulsants
- Sodium Channel Blockers
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Lamotrigine
Other Study ID Numbers
- 113783
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Mayo ClinicCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Medical University of South CarolinaMilken InstituteCompletedBipolar Disorder | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Myriad Genetic Laboratories, Inc.University of MinnesotaCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
University Hospital, Strasbourg, FranceUnknownBipolar Disorder I | Bipolar Disorder II | Rapid Cycling Bipolar Disorder(DSM-IV-TR)France
-
Universiteit AntwerpenUniversitair Ziekenhuis BrusselUnknownDepression | Mood Disorders | Bipolar Disorder | Bipolar Depression | Mental Disorder | Bipolar I Disorder | Bipolar II DisorderBelgium
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States